A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors

Trial Profile

A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Fluzoparib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Atridia; Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 23 Apr 2017 Planned End Date changed from 1 Nov 2020 to 1 Dec 2018.
    • 23 Apr 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2018.
    • 14 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top